Jazz Pharmaceuticals Presents Data from Safety Trial of Patients Treated with Erwinaze
Posted on December 10, 2012 at 19:24 PM EST
Jazz Pharmaceuticals (NASDAQ: JAZZ ) today announced that data from the largest safety trial to date of patients treated with Erwinaze® (asparaginase Erwinia chrysanthemi) have been presented at the American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia. The poster, titled "L-Asparaginase (L-ASP) Related Toxicities with